Skip to content
Optionomics Free · No account needed

Earnings analysis · 10-K

HAE earnings analysis

Filed May 20, 2026 · Our reading of the company's report

The latest report

Haemonetics reported FY2026 financial results with a net revenue of $1,334 million, down 2.0% from FY2025, impacted by the divestiture of the Whole Blood product line and customer transitions. Gross margins improved to…

Read full summary

Haemonetics reported FY2026 financial results with a net revenue of $1,334 million, down 2.0% from FY2025, impacted by the divestiture of the Whole Blood product line and customer transitions. Gross margins improved to 59% from 55% in the previous year, although operating income decreased by 29.3% due to significant intangible asset impairments. The company expects a revenue growth of 4% to 7% in FY2027, driven by gains in Hospital and Plasma segments, despite challenges in the Blood Center segment.

Read the original on SEC.gov

From revenue to operating profit

Where each $100 of revenue went in this report.

Of every $100 of revenue Cost of sales $41 Operating expenses $47 Left as operating profit $12

Cost of sales, operating expenses, and what remained. Figures are rounded to whole dollars.

Reported figures

Earnings per share
$2.05
Segment
Plasma
Segment
Blood Center
Segment
Hospital

What stood out

  • Strong Organic Growth in Hospital Segment

    Hospital revenues rose 4.3% to $588 million, fueled by Hemostasis Management and Transfusion Management products.

  • Repurchased $175M in Common Stock

    Under the share repurchase program authorized up to $500 million, the company bought back $175 million in fiscal 2026.

  • Improved Gross Margin

    Gross margin increased to 59% in FY2026, up from 55% in FY2025, reflecting stronger pricing and product innovation.

  • Acquisition of Vivasure Medical

    Acquired Vivasure Medical for $164.4 million, expanding Hospital's portfolio with new technologies on January 9, 2026.

  • Operating Cash Flow Growth

    Operating cash flow improved to $293 million in FY2026 from $182 million in FY2025, aided by better working capital management.

  • Non-recurring Sales Loss Impact

    Sales of $153 million from previous non-recurring portfolio transitions adversely affected revenue for FY2026.

What to watch

  • Significant Impairment Charges

    Impairment of intangible assets totaled $86.5 million in FY2026, significantly affecting profitability.

  • Sales Decline in Blood Center

    Blood Center revenues fell by 15.3% to $221 million, largely due to the divestiture of the Whole Blood product line.

  • Market Risk from Inflation and Costs

    Rising inflation and unpredictable market dynamics pose ongoing risks to the company's operational costs and margins.

Management's outlook

The company expects revenue growth of 4% to 7% in FY2027, supported by performance improvements in the Hospital and Plasma segments.

This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.